Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on January 13, 2009
JNCI Journal of the National Cancer Institute 2009 101(2):69; doi:10.1093/jnci/djp003
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/2/69-b    most recent
djp003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

MEMO TO THE MEDIA

HPV Testing Followed by Cytology and Repeat HPV Testing May Improve Cervical Cancer Screening

The use of human papillomavirus (HPV) DNA testing as an initial screening step followed by triage with a standard Pap test (cytology) and repeat HPV DNA testing may increase the accuracy of cervical cancer screening, according to a study in the Jan. 13 online issue of the Journal of the National Cancer Institute. Compared to cytology alone, the screening strategy improved detection of precancerous growths without a substantial increase in the number of false-positive tests.

Randomized trials have shown that using DNA testing for HPV—which is known to cause cervical cancer—in screening programs would increase detection of cervical intraepithelial neoplasia (CIN) compared with cytology. However, HPV DNA testing also results in a substantial increase in false-positive tests, which lead to unnecessary and costly retesting.

In the current study, Joakim Dillner, M.D. of Lund University in Malmö, Sweden, and colleagues compared the efficacy of 11 different screening strategies that used HPV DNA testing, cytology, or a combination of the two. To evaluate the different strategies the investigators retrospectively analyzed data from 6,257 women who were enrolled in the intervention arm of a large randomized screening trial, called Swedescreen, in which HPV DNA testing was used in addition to standard cytology.

As seen in previous trials, the use of HPV DNA testing in conjunction with cytology increased the screening efficacy, detecting 35 percent more cases of CIN grade 3 or worse, compared with cytology alone. The strategy, however, doubled the number of tests required. By contrast, the use of the HPV primary screen with cytology and repeat HPV testing resulted in a 30 percent higher detection rate compared to cytology alone, with only a 12 percent increase in the number of tests required. In this approach, all women with HPV infections detected on the primary screening went on to have a standard Pap test; those with normal cytology then had a repeat HPV DNA test at least 1 year later.

"In conclusion, our data indicate that using HPV DNA testing as primary screening followed by cytological triage and repeat HPV DNA testing of women with normal cytology who are HPV DNA positive after at least 1 year is a feasible strategy for incorporating HPV testing in primary cervical screening because it improves sensitivity and maintains a high [positive predictive value], thus minimizing unnecessary referrals," the authors write.

Contact:

  • Joakim.Dillner{at}med.lu.se; phone: +46 40 338126

Citation:

  • Naucler P, et al. Efficacy of HPV DNA Testing with Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening. J Natl Cancer Inst 2009;101: 88–99.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening
Pontus Naucler, Walter Ryd, Sven Törnberg, Anders Strand, Göran Wadell, Kristina Elfgren, Thomas Rådberg, Björn Strander, Ola Forslund, Bengt-Göran Hansson, Björn Hagmar, Bo Johansson, Eva Rylander, and Joakim Dillner
J Natl Cancer Inst 2009 101: 88-99. [Abstract] [Full Text] [PDF]




This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/2/69-b    most recent
djp003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?